Johnson & Johnson experienced a strong first quarter with solid sales and earnings performances, highlighted by the beneficial impact of ZYRTECâ€™s OTC launch, inventory build effects, and product pipeline progress. However, the short-term stock price might face pressure due to concerns over economic slowdowns affecting procedure volumes and increased competition in key areas like drug-eluting stents and ESAs for PROCRIT, though these are counteracted by their positive guidance update and resilience of their consumer business.
[0]